Insights

GPCR Focus Target an org with a specialized GPCR platform offering biased mu-opioid receptor agonist candidates (MEB-1170) and IND-ready assays, presenting a compelling collaboration or licensing opportunity for pain, OUD, and CNS programs.

Clinical Progress Leverage their Phase I activity and clinical-stage compound to position as a fast-path co-development partner for analgesics and opioid use disorder therapeutics, reducing time to clinic for potential licensees.

Strategic Funding Identify potential investors or joint funding prospects by engaging with their existing backers (BioAdvance, Viva BioInnovator, Life Science Angels) for co-development finance and expanded research initiatives.

Cost-Effective Discovery Highlight the platform’s ability to shorten lead optimization and reduce on-target adverse events, offering cost-efficiencies to partners seeking IND-ready candidates in CNS, Pain, Metabolic, and Inflammatory areas.

Small Team, Big Scope Position as a nimble collaboration partner with access to native GPCR purification and NMR capabilities, appealing to larger biotechs seeking agile early-stage discovery and strategic outsourcing.

Similar companies to Mebias Discovery, Inc

Mebias Discovery, Inc Tech Stack

Mebias Discovery, Inc uses 8 technology products and services including gstatic.com, WordPress, oEmbed, and more. Explore Mebias Discovery, Inc's tech stack below.

  • gstatic.com
    Content Delivery Network
  • Content Management System
  • oEmbed
    Dev Tools
  • E-commerce
  • jQuery Mobile
    Mobile Frameworks
  • PHP
    Programming Languages
  • mod_jk
    Web Server Extensions

Mebias Discovery, Inc's Email Address Formats

Mebias Discovery, Inc uses at least 1 email format:
Mebias Discovery, Inc Email FormatsExamplePercentage
First.Last@mebiasdiscovery.comJohn.Doe@mebiasdiscovery.com
100%

Frequently Asked Questions

What is Mebias Discovery, Inc's official website and social media links?

Minus sign iconPlus sign icon
Mebias Discovery, Inc's official website is mebiasdiscovery.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Mebias Discovery, Inc generate?

Minus sign iconPlus sign icon
As of September 2026, Mebias Discovery, Inc's annual revenue is estimated to be $1M - $10M.

What is Mebias Discovery, Inc's SIC code and NAICS code?

Minus sign iconPlus sign icon
Mebias Discovery, Inc's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Mebias Discovery, Inc have currently?

Minus sign iconPlus sign icon
As of September 2026, Mebias Discovery, Inc has approximately 4 employees across 1 continents, including North America. Key team members include Chief Medical Officer: S. R. and Board Member: S. V. Explore Mebias Discovery, Inc's employee directory with LeadIQ.

What industry does Mebias Discovery, Inc belong to?

Minus sign iconPlus sign icon
Mebias Discovery, Inc operates in the Biotechnology Research industry.

What technology does Mebias Discovery, Inc use?

Minus sign iconPlus sign icon
Mebias Discovery, Inc's tech stack includes gstatic.com, WordPress, oEmbed, Shopify, Google Workspace, jQuery Mobile, PHP and mod_jk.

What is Mebias Discovery, Inc's email format?

Minus sign iconPlus sign icon
Mebias Discovery, Inc's email format typically follows the pattern of First.Last@mebiasdiscovery.com. Find more Mebias Discovery, Inc email formats with LeadIQ.

How much funding has Mebias Discovery, Inc raised to date?

Minus sign iconPlus sign icon
As of September 2026, Mebias Discovery, Inc has raised $5M in funding. The last funding round occurred on Oct 23, 2022 for $631K.

When was Mebias Discovery, Inc founded?

Minus sign iconPlus sign icon
Mebias Discovery, Inc was founded in 2015.
Mebias Discovery, Inc logo

Mebias Discovery, Inc

Biotechnology ResearchPennsylvania, United States2-10 Employees

Mebias Discovery, Inc. is a Philadelphia-based biotechnology company focused on discovering drugs that target G-protein coupled receptors. The firm aims to identify next-generation GPCR therapeutics with fewer on-target side effects by examining how receptors move and signal. Its platform relies on validated assays that link ligand-induced receptor conformations to pharmacologic outcomes, and the team is described as small and science-driven.

Its initial focus areas include CNS-related conditions, pain, opioid use disorder, as well as metabolic and inflammatory disorders. A lead mu-opioid receptor program, MEB-1170, is presented as a differentiated biased agonist with a profile that reportedly avoids key liabilities such as respiratory depression, tolerance, and abuse potential. Public notes indicate MEB-1170 entered Phase I clinical development in late 2022, and the company publicly seeks co-development or licensing arrangements and collaborations to advance additional targets.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
2-10

Section iconFunding & Financials

  • $5M

    Mebias Discovery, Inc has raised a total of $5M of funding over 5 rounds. Their latest funding round was raised on Oct 23, 2022 in the amount of $631K as a Venture Round.

  • $1M - $10M

    Mebias Discovery, Inc's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.